OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
February 25, 2021
Under the terms of the partnership, ICQ Consultants will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa's bioreactor systems and related products in the US.
The company will join the network of approved manufacturers of the lipid excipients.
The site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization.
February 24, 2021
The expansion, to be completed in April 2021 aims to increase the CDMO’s viral-vector production capacity in Spain.
Through the acquisition, PharmaLex will expand its capabilities in the biopharma sector while enhancing its global market reach with a new location in Australia.
February 23, 2021
The new facility is part of Bristol Myers Squibb’s investment into the clinical and commercial manufacturing of cell therapies for patients with aggressive hematological cancers.
Through the acquisition, Catalent will establish pDNA development and manufacturing services at its Rockville, MD, facility and will gain Delphi’s team of R&D and genetic engineering scientists, technicians, and regulatory specialists.
Aprecia's compression-free 3DP manufacturing platform and Glatt’s multiparticulate technologies offer solutions to pharmaceutical dosage design challenges.
February 22, 2021
With the acquisition, Eurofins gets Beacon’s G-protein coupled receptor research knowledge and its compound library.
Once the vaccine has been authorized, Sanofi will provide Johnson & Johnson with access to its vaccine manufacturing plant in Marcy l’Etoile, France, to formulate and fill vials of the vaccine, at a rate of 12 million doses per month.
The second phase of the Myford facility expansion in California will add upstream and downstream processing suites.
February 18, 2021
The company has completed the expansion of its laboratory facilities to accommodate the development of APIs.
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
Through the agreement, Catalent will manufacture LUPKYNIS (voclosporin), Aurinia’s drug for the treatment of adult patients with lupus nephritis, at its pharmaceutical softgel center of excellence in St. Petersburg, FL.
The companies have expanded their agreement to include the research and development of new therapies for influenza and other respiratory viruses.
Cascade began production on new facilities to manufacture APIs for clinical and commercial GMP production.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.
Salipro Biotech has been granted a European Patent for its novel method of direct extraction of membrane proteins and for the generation of libraries with Salipro particles.
February 16, 2021
The increased services will work in conjunction with the site’s SimpliFiH Solutions first-in-human services, which includes phase-appropriate drug substance and drug product development and manufacturing.